Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA Save
A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).
A retrospective analysis of pooled safety data from 10 phase 3 clinical trials of adult RA patients on MTX who were treatd with either ABA or placebo and assess for ILD events (may have included acute respiratory events suggestive of pneumonitis/ILD). Data was drawn from the following trials: AGREE, ATTEST, AIM, ALLOW, ACCOMPANY, ACQUIRE, AVERT, AMPLE, AVERT-2, and early AMPLE. While ILD was not an exclusion criterion for most trials, the AMPLE trial excluded those with severe, progressive, or uncontrolled pulmonary disease. Therefore, some patients may have had pre-existing RA-ILD at baseline.
The analysis compared ABA plus MTX treated (n: 3708 and 10,521 person-years) to placebo plus MTX (n 999, and person-years). Abatacept + MTX had:
- lower rate of ILD events (IR 0.10; 0.05–0.18 versus 0.43; 0.16–1.14)
- Fewer hospitalizations
- lower rates for ILD in: Patients with RA aged ≥ 55 years, body mass index < 30 kg/m2, no history of smoking, no baseline disease-modifying antirheumatic drug use other than MTX, no prior tumor necrosis factor inhibitor use, high DAS28-CRP, and rheumatoid factor or anti-citrullinated protein antibody positivity who were receiving corticosteroid(s)
Aggressive combination therapy with ABA and MTX may lower the risk of future ILD. Such findings merit further study and analysis in other cohorts and prospective studies.
Join The Discussion
The positive results here were shown in newly diagnosed seropositive patients with high disease activity who were on steroids. If we looked back at the same way on other therapies employed vs. placebo in naive patients, I wonder if we would see a more or less similar trend in all other MOAs? Also, does the window of opportunity concept in early RA apply to early ILD?
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.